Passive and Active Anti-Hepatitis B Immunization of Children with Hematological Malignancies

  • J. Bogusławska-Jaworska
  • E. Gorczyńska
  • H. Seyfried
  • A. Gładysz
  • M. Zalewska
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 30)

Abstract

The risk of hepatitis B virus (HBV) infection is evidently higher in children with hematological malignancies than in the general population [1–4] Unlike healthy children, a high proportion of those receiving chemotherapy for leukemia and lymphoma who are infected with HBV become chronic carriers [4]. Most of them remain highly contagious throughout the cytostatic therapy. Their infectivity is associated with a frequent occurrence of HBV antigen in their tissues and body fluids and its excretion in saliva and urine [5]. Controlling the HBV infection chain is a difficult problem. The passive and active specific immunization may provide the solution. In this paper we report results of the study on the efficacy of the two different immunization formulae which we used during the epidemic in 1982–1985.

Keywords

Hepatitis Lymphoma Leukemia Alanine Transferase 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Baraldini M, Miglio F, Pirillo L, Cursaro C, Meliconi R, Stefanini GF, Gasbarrini G (1973) Hepatitis B virus markers in hematologic patients: relation to transfusion treatment and hospitalisation. Vox Sang 45: 112–120CrossRefGoogle Scholar
  2. 2.
    Entacher U, Jürgenssen O, Thun-Hohenstein L, Simbruner G, Khoss A, Wank H, Neuwirth G, Gadner H, Frisch-Niggemeyer W (1985) Hepatitis B vaccination and immune response 8. in children with malignant diseases. Eur J Pediatr 144: 160–163PubMedCrossRefGoogle Scholar
  3. 3.
    Locasciulli A, Alberti A, Rossetti F, Santamaria M, et al. (1985) Acute and chronic hepatitis in childhood leukemia: multicentric study from Italian Pediatric Cooperative Group for Therapy of Acute Leukemia. Med Pediatr On-col 13: 203–206CrossRefGoogle Scholar
  4. 4.
    Kościelniak E, Boguslawska-Jaworska J (1983) Zakazenie wirusem zapalenia watroby typu B u dzieci z chorobami ukladu krwiotwórczego i limfatycznego. Pediatr Pol 48: 7–13Google Scholar
  5. 5.
    Sung IL, Chen DS (1983) Hepatitis B surface antigen in saliva, urine and ascites. Hepatogastroenterology 30: 183–185Google Scholar
  6. 6.
    Henze G, Langermann H-J, Ritter J, Schellong G, Rhiem H (1981) Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia: a report from the BFM Study Group. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern trends in human leukemia, vol 4. Springer, Berlin Heidelberg New York pp 87–93Google Scholar
  7. 7.
    Creuzig U, Ritter J, Langermann HJ, Rhiem H, Henze G, Niethammer D, Jürgens H, Stollmann B, Lasson U, Kabisch H, Wahlen W, Löffler H, Schellong G (1983) Akute myeloische Leukämie bei Kindern: Ergebnisse der Kooperativen Therapiestudie BFM 78 nach 33/4 Jahren. Klin Pädiatr 195: 152–160CrossRefGoogle Scholar
  8. 8.
    Wollner N, Burchanal JH, Liebermann PH (1975) Non-Hodgkin’s lymphoma in children. Med Pediatr Oncol 1: 235–263PubMedCrossRefGoogle Scholar
  9. 9.
    Grob PJ, Binswanger U, Zaruba K (1983) Immunogenicity of a hepatitis B subunit vaccine in haemodialysis and in renal transplant recipients. Antiviral Res 3: 43–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • J. Bogusławska-Jaworska
    • 1
    • 2
    • 3
  • E. Gorczyńska
  • H. Seyfried
  • A. Gładysz
  • M. Zalewska
  1. 1.Department of Pediatric HematologyMedical SchoolWroclawPoland
  2. 2.Department of SerologyInstitute of HematologyWarsawPoland
  3. 3.Department of Infections DiseasesMedical SchoolWroclawPoland

Personalised recommendations